HIFU Ablation of Soft Tissue Sarcoma

Around 3,300 people are diagnosed with soft tissue sarcoma (STS) each year in the UK, and a significant proportion of STS diagnoses are in people aged under 30 years. STS can arise from various tissue types and is comprised of over 50 tumour types. Although STS is treated with a combination of surgery, radiotherapy and chemotherapy, the prognosis is relatively poor with a five-year survival rate of 54%. There is an unmet need for further treatment modalities in STS. High intensity focused ultrasound (HIFU) is a non-invasive way of treating cancers with minimal side effects, low complication r

Trial Details

NCT ID
NCT05111964
Phase
NA
Sponsor
Oxford University Hospitals NHS Trust
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • High Intensity Focused Ultrasound Ablation
  • Tumour Biopsy and Venous Blood Tests
Locations (sample)
  • Oxford, Oxfordshire, United Kingdom|51.75222,-1.25596

Key Eligibility Criteria

  • The participant is eligible for the study if they are:
  • Willing and able to give informed consent for participation in the study.
  • Aged 18 years or above.
  • Diagnosed with histologically-confirmed and HIFU-targetable soft tissue sarcoma of several subtypes, including but not necessarily limited to:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →